71003 71003

Docket No.: PF-0333-2 DIV

ate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Printed:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bandman et al.

Title:

HUMAN EXTRACELLULAR MATRIX PROTEINS

Serial No.:

09/836,561

Filing Date:

April 16, 2001

Examiner:

Huff, S

Group Art Unit:

1642

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "Supplemental List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants becentured to Applicants.

For the Examiner's convenience, Applicants have enclosed a sequence alignment and the NCBI page describing the submitted sequence.

07/15/2003 KDOWNING 00000002 0901

111090

09/836,561

Docket No.: PF-0333-2 DIV

The listed reference was just recently discovered by Applicants and is being submitted to the Examiner within three months of this discovery.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108.

If there are any questions regarding the above, the Examiner is invited to call the undersigned.

Respectfully submitted,

INCYTE CORPORATION

James M. Verna, Ph.D.

Reg. No. 33,287

Direct Dial Telephone: (650) 845 -5415

Customer No.: 27904 3160 Porter Drive

Palo Alto, California 94304

Phone: (650) 855-0555 Fax: (650) 845-4166

Enclosures:

Sequence Alignment

NCBI page of submitted sequence